PMID- 32696866
OWN - NLM
STAT- MEDLINE
DCOM- 20200807
LR  - 20200807
IS  - 1806-9282 (Electronic)
IS  - 0104-4230 (Linking)
VI  - 66
IP  - 6
DP  - 2020 Jun
TI  - TMPO-AS1 is an independent prognostic factor for patients with laryngeal squamous 
      cell carcinoma.
PG  - 784-788
LID - S0104-42302020000600784 [pii]
LID - 10.1590/1806-9282.66.6.784 [doi]
AB  - OBJECTIVE Long noncoding RNA (lncRNAs) are frequently abnormally expressed in 
      tumors and involved in the occurrence and progression of human cancer. Recently, 
      a disease-related lncRNA, TMPO antisense RNA 1 (TMPO-AS1), was identified to be 
      dysregulated in several tumors. Hence, we aimed to demonstrate whether TMPO-AS1 
      could be a promising prognostic marker for patients with laryngeal squamous cell 
      carcinoma (LSCC). METHODS RT-PCR was performed to test TMPO-AS1 expressions in 
      187 LSCC specimens compared with matched normal specimens. Chi-squared tests were 
      used to determine the associations between TMPO-AS1 expressions and the 
      clinicopathological characteristics of LSCC patients. Then, the clinical outcome 
      of LSCC patients who had lower or higher TMPO-AS1 expression was analyzed using 
      Kaplan-Meier assays. Finally, a Cox proportional hazards model was carried out to 
      evaluate the prognostic values of TMPO-AS1 and other clinical features. RESULTS 
      We found that TMPO-AS1 was distinctly upregulated in human LSCC tissues compared 
      with corresponding normal specimens (p < 0.01). Higher expressions of TMPO-AS1 
      were observed to be positively associated with the clinical stage (p = 0.020) and 
      lymph node metastasis (p = 0.027). A clinical study in 187 patients revealed that 
      patients with TMPO-AS1 low expressions had poorer survival than those with 
      TMPO-AS1 high expressions (p = 0.0012). In addition, the result of multivariate 
      assays demonstrated TMPO-AS1 expression is an independent predictor for the 
      overall survival of LSCC patients. CONCLUSIONS TMPO-AS1 might be considered a 
      novel molecule involved in LSCC progression, which provides a possible prognostic 
      biomarker.
FAU - Zhang, Lihua
AU  - Zhang L
AD  - Department of Outpatient, Taian City Central Hospital, Taian, Shandong, China.
FAU - Zhang, Yu
AU  - Zhang Y
AD  - Department of Respiratory Medicine, Taian City Central Hospital, Taian, Shandong, 
      China.
FAU - Zhang, Chunjie
AU  - Zhang C
AD  - Department of Obstetrics, Taian City Central Hospital, Taian, Shandong, China.
FAU - Hou, Yun
AU  - Hou Y
AD  - Department of Obstetrics, Taian City Central Hospital, Taian, Shandong, China.
FAU - Tian, Fang
AU  - Tian F
AD  - Medical Care Center, Taian City Central Hospital, Taian, Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20200720
PL  - Brazil
TA  - Rev Assoc Med Bras (1992)
JT  - Revista da Associacao Medica Brasileira (1992)
JID - 9308586
RN  - 0 (Cyclic N-Oxides)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (Thymopoietins)
RN  - 10135-38-3 (3,3,5,5-tetramethyl-1-pyrroline N-oxide)
SB  - IM
MH  - Carcinoma, Squamous Cell/*diagnosis
MH  - Cyclic N-Oxides
MH  - Humans
MH  - Laryngeal Neoplasms/*diagnosis
MH  - Prognosis
MH  - RNA, Long Noncoding
MH  - Thymopoietins/*metabolism
EDAT- 2020/07/23 06:00
MHDA- 2020/08/08 06:00
CRDT- 2020/07/23 06:00
PHST- 2019/12/30 00:00 [received]
PHST- 2020/01/19 00:00 [accepted]
PHST- 2020/07/23 06:00 [entrez]
PHST- 2020/07/23 06:00 [pubmed]
PHST- 2020/08/08 06:00 [medline]
AID - S0104-42302020000600784 [pii]
AID - 10.1590/1806-9282.66.6.784 [doi]
PST - ppublish
SO  - Rev Assoc Med Bras (1992). 2020 Jun;66(6):784-788. doi: 
      10.1590/1806-9282.66.6.784. Epub 2020 Jul 20.